Advertisement
ABT vs ALC
Which Stock Would AI Choose? Abbott Laboratories (ABT) vs. Alcon Inc. (ALC) Stock Comparison
Key Takeaways
- Abbott Laboratories (ABT) and Alcon Inc. (ALC) operate in adjacent healthcare segments but with distinct business profiles — Abbott is a diversified healthcare conglomerate, while Alcon is a pure-play eye care specialist.
- Both stocks have demonstrated resilience in the medical device and healthcare consumables space, though their growth drivers and risk exposures differ meaningfully.
- Abbott's diversified portfolio across diagnostics, medical devices, nutrition, and pharmaceuticals provides revenue stability, while Alcon's concentrated focus on surgical and vision care offers higher exposure to sector-specific tailwinds.
- Recent market activity reflects contrasting reactions to earnings, product pipeline developments, and broader healthcare sector rotation.
- AI-driven analysis from Tickeron's platform offers a data-backed perspective on which stock currently exhibits stronger trend consistency and relative positioning.
Introduction
Healthcare stocks have long been a cornerstone of defensive and growth-oriented portfolios alike, and few pairings illustrate the sector's diversity better than ABT and ALC. Abbott Laboratories stands as one of the world's largest diversified healthcare companies, while Alcon has carved out a dominant niche as a global leader in eye care. Both companies generate substantial revenue, maintain strong brand recognition, and benefit from secular healthcare trends such as aging populations and expanding access to medical procedures. This comparison examines their recent performance, business fundamentals, and market positioning to help traders and investors assess how these two healthcare names stack up in the current environment.
ABT Overview and Recent Performance
Abbott Laboratories (ABT) is a diversified healthcare giant with operations spanning medical devices, diagnostics, branded generic pharmaceuticals, and nutritional products. Its flagship continuous glucose monitor, FreeStyle Libre, has been a key growth engine, while its diagnostics segment gained prominence during the pandemic and continues to evolve with a broader testing portfolio. In recent weeks, Abbott's share price has generally reflected a steady, range-bound character, supported by consistent earnings performance and a reliable dividend history. The company's diversified revenue streams have helped it weather sector-specific headwinds better than many pure-play peers. Recent market activity has been influenced by quarterly earnings results that generally met or modestly exceeded expectations, along with ongoing product innovation updates. Investors have also been attentive to Abbott's pipeline developments in medtech and the pace of recovery in its nutrition segment. Broadly, sentiment around ABT has remained relatively constructive, though the stock's large-cap, mature profile means dramatic price swings are uncommon outside of major catalysts.
ALC Overview and Recent Performance
Alcon Inc. (ALC), spun off from Novartis in 2019, is the world's largest eye care device company. Its business is split between two segments: Surgical, which includes implantable lenses, consumables, and equipment for cataract and refractive procedures; and Vision Care, which covers contact lenses and ocular health products, including the popular DAILIES TOTAL1 and Systane brands. Over recent months, Alcon has benefited from a robust recovery in surgical volumes, driven by aging demographics and pent-up demand for elective procedures. The company's recent financial reports have highlighted strong top-line growth, and management has raised guidance, reflecting confidence in sustained momentum. Stock performance has generally trended positively, with Alcon showing a relatively stronger upward trajectory compared to many peers in the medical device space. Key tailwinds include the launch of advanced-technology intraocular lenses (IOLs), expansion in international markets, and a growing installed base of surgical equipment. Sentiment around ALC has been buoyed by these catalysts, though investors remain mindful of foreign exchange exposure and competitive dynamics in the contact lens market.
Trending AI Robots
For traders seeking a data-driven edge, Tickeron's Trending AI Robots page offers a curated selection of AI-powered trading bots designed to adapt to evolving market conditions. Tickeron hosts hundreds of AI trading bots that collectively trade thousands of different tickers, but only the most consistent and market-aligned performers earn a spot in this featured section. These bots employ diverse trading strategies — ranging from swing trading and trend following to mean reversion and breakout models — across various timeframes and asset classes. Many of these bots showcase win rates exceeding 70%, with some demonstrating annualized returns that significantly outpace benchmark indices, though individual bot performance and statistics vary based on strategy, market regime, and the tickers they trade. Exploring the Trending AI Robots section can help traders identify algorithmically driven opportunities tailored to current market dynamics.
Head-to-Head Comparison
While both ABT and ALC operate in healthcare, their investment profiles differ considerably. Abbott's diversification across four major business segments provides built-in risk mitigation — weakness in one area can be offset by strength in another. Alcon, by contrast, is highly concentrated in eye care, which amplifies upside during favorable industry cycles but also increases vulnerability to surgical volume disruptions or competitive pressures. On the growth front, Alcon has recently exhibited more pronounced momentum, fueled by its narrower, high-growth focus and product innovation cycle. Abbott, meanwhile, offers steadier, compounding returns supported by its established franchises and dividend growth. From a valuation standpoint, the two stocks often trade at different multiples reflecting their respective growth rates and business complexity. Sector exposure also diverges: Abbott's diagnostics and nutrition businesses give it consumer staples-like characteristics, while Alcon is more aligned with elective medical procedures and discretionary healthcare spending. Risk factors include regulatory changes and reimbursement policy for both, though currency fluctuations and emerging-market exposure tend to impact Alcon more acutely.
Tickeron AI Verdict
Based on observable trend indicators, momentum patterns, and relative positioning analyzed through Tickeron's AI framework, ALC currently appears to hold a modest edge over ABT. The AI's assessment leans on Alcon's more pronounced positive trend consistency in recent weeks, stronger earnings-driven catalysts, and favorable positioning within the surgical recovery theme. Abbott remains a high-quality, resilient holding with strong fundamentals, but its recent price action has exhibited a more neutral, consolidation-oriented pattern that suggests less near-term directional conviction. Tickeron's AI would likely favor Alcon for trend-following strategies in the current environment, while recognizing Abbott's appeal for risk-averse, income-oriented positioning. As always, this probabilistic assessment reflects current data and market conditions, which can shift as new information emerges.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Disclaimers and LimitationsTo compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ABT is a Buy and ALC is a StrongBuy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ABT’s FA Score shows that 2 FA rating(s) are green whileALC’s FA Score has 0 green FA rating(s).
- ABT’s FA Score: 2 green, 3 red.
- ALC’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ABT’s TA Score shows that 6 TA indicator(s) are bullish while ALC’s TA Score has 6 bullish TA indicator(s).
- ABT’s TA Score: 6 bullish, 4 bearish.
- ALC’s TA Score: 6 bullish, 3 bearish.
Price Growth
ABT (@Medical/Nursing Services) experienced а +2.36% price change this week, while ALC (@Pharmaceuticals: Other) price change was -3.34% for the same time period.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -5.78%. For the same industry, the average monthly price growth was -7.49%, and the average quarterly price growth was -21.89%.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was -3.53%. For the same industry, the average monthly price growth was -1.01%, and the average quarterly price growth was -10.46%.
Reported Earning Dates
ABT is expected to report earnings on Oct 21, 2026.
ALC is expected to report earnings on Aug 10, 2026.
Industries' Descriptions
@Medical/Nursing Services (-5.78% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
@Pharmaceuticals: Other (-3.53% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
| ABT | ALC | ABT / ALC | |
| Capitalization | 180B | 33.4B | 539% |
| EBITDA | 11.8B | 2.54B | 465% |
| Gain YTD | -16.214 | -13.831 | 117% |
| P/E Ratio | 33.35 | 40.66 | 82% |
| Revenue | 45.1B | 10.6B | 425% |
| Total Cash | N/A | 1.66B | - |
| Total Debt | 34B | 5.25B | 647% |
ABT | ALC | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 37 | 9 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 4 Undervalued | 54 Fair valued | |
PROFIT vs RISK RATING 1..100 | 98 | 100 | |
SMR RATING 1..100 | 64 | 88 | |
PRICE GROWTH RATING 1..100 | 48 | 61 | |
P/E GROWTH RATING 1..100 | 11 | 50 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ABT's Valuation (4) in the Medical Specialties industry is somewhat better than the same rating for ALC (54) in the Hospital Or Nursing Management industry. This means that ABT’s stock grew somewhat faster than ALC’s over the last 12 months.
ABT's Profit vs Risk Rating (98) in the Medical Specialties industry is in the same range as ALC (100) in the Hospital Or Nursing Management industry. This means that ABT’s stock grew similarly to ALC’s over the last 12 months.
ABT's SMR Rating (64) in the Medical Specialties industry is in the same range as ALC (88) in the Hospital Or Nursing Management industry. This means that ABT’s stock grew similarly to ALC’s over the last 12 months.
ABT's Price Growth Rating (48) in the Medical Specialties industry is in the same range as ALC (61) in the Hospital Or Nursing Management industry. This means that ABT’s stock grew similarly to ALC’s over the last 12 months.
ABT's P/E Growth Rating (11) in the Medical Specialties industry is somewhat better than the same rating for ALC (50) in the Hospital Or Nursing Management industry. This means that ABT’s stock grew somewhat faster than ALC’s over the last 12 months.
| ABT | ALC | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 53% | N/A |
| Stochastic ODDS (%) | 2 days ago 45% | 2 days ago 59% |
| Momentum ODDS (%) | 2 days ago 51% | 2 days ago 67% |
| MACD ODDS (%) | 2 days ago 46% | 2 days ago 57% |
| TrendWeek ODDS (%) | 2 days ago 51% | 2 days ago 49% |
| TrendMonth ODDS (%) | 2 days ago 48% | 2 days ago 55% |
| Advances ODDS (%) | 2 days ago 54% | 10 days ago 57% |
| Declines ODDS (%) | 12 days ago 54% | 5 days ago 55% |
| BollingerBands ODDS (%) | 2 days ago 53% | 2 days ago 55% |
| Aroon ODDS (%) | 2 days ago 48% | 2 days ago 40% |
Advertisement
ABT and
Correlation & Price change
A.I.dvisor indicates that over the last year, ABT has been loosely correlated with MDT. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if ABT jumps, then MDT could also see price increases.
ALC and
Correlation & Price change
A.I.dvisor indicates that over the last year, ALC has been loosely correlated with SYK. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if ALC jumps, then SYK could also see price increases.